Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies

被引：8
|
作者：
Fragoso, Natalie M. [1 ]
Masson, Rahul [2 ]
Gillenwater, T. Justin [3 ]
Shi, Vivian Y. [4 ]
Hsiao, Jennifer L. [5 ]
机构：
[1] Dartmouth Hitchcock Med Ctr, Dept Dermatol, Lebanon, NH USA
[2] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA
[3] Univ Southern Calif, Div Plast & Reconstruct Surg, Los Angeles, CA USA
[4] Univ Arkansas Med Sci, Dept Dermatol, Little Rock, AR USA
[5] Univ Southern Calif, Dept Dermatol, 1441 Eastlake Ave,Ezralow Tower,Suite 5301, Los Angeles, CA 90089 USA
来源：
DERMATOLOGY AND THERAPY | 2023年 / 13卷 / 08期
关键词：
Clinical trials; Hidradenitis suppurativa; Systemic; Topical; Treatment; DOUBLE-BLIND; MODERATE; ADALIMUMAB; CANAKINUMAB; INHIBITOR; SAFETY; ALPHA; PHARMACOKINETICS; MULTICENTER; SECUKINUMAB;
D O I：
10.1007/s13555-023-00956-6
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Hidradenitis suppurativa (HS) is an oftentimes debilitating condition that presents with painful nodules, abscesses, and sinus tracts. This condition is challenging to treat, in part because the pathogenesis of the condition is incompletely understood but also because there are limited therapeutic options. HS research is undergoing explosive growth with multiple new molecular pathways under study, which will hopefully lead to improved disease control for patients. Part I of this review will provide an overview of the emerging topical and systemic therapies under investigation for HS.
引用
收藏
页码：1661 / 1697
页数：37
相关论文
共 19 条
  • [1] Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies
    Natalie M. Fragoso
    Rahul Masson
    T. Justin Gillenwater
    Vivian Y. Shi
    Jennifer L. Hsiao
    Dermatology and Therapy, 2023, 13 : 1661 - 1697
  • [2] Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa—Part II: Procedural and Wound Care Therapies
    Natalie M. Fragoso
    Rahul Masson
    T. Justin Gillenwater
    Vivian Y. Shi
    Jennifer L. Hsiao
    Dermatology and Therapy, 2023, 13 : 1699 - 1720
  • [3] Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa-Part II: Procedural and Wound Care Therapies
    Fragoso, Natalie M.
    Masson, Rahul
    Gillenwater, T. Justin
    Shi, Vivian Y.
    Hsiao, Jennifer L.
    DERMATOLOGY AND THERAPY, 2023, 13 (08) : 1699 - 1720
  • [4] Emerging medical treatments for hidradenitis suppurativa
    Lyons, Alexis B.
    Shabeeb, Nadine
    Nicholson, Cynthia L.
    Braunberger, Taylor L.
    Peacock, Anjelica
    Hamzavi, Iltefat H.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (02) : 554 - 562
  • [5] North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations Part II: Topical, intralesional, and systemic medical management
    Alikhan, Ali
    Sayed, Christopher
    Alavi, Afsaneh
    Alhusayen, Raed
    Brassard, Alain
    Burkhart, Craig
    Crowell, Karen
    Eisen, Daniel B.
    Gottlieb, Alice B.
    Hamzavi, Iltefat
    Hazen, Paul G.
    Jaleel, Tara
    Kimball, Alexa B.
    Kirby, Joslyn
    Lowes, Michelle A.
    Micheletti, Robert
    Miller, Angela
    Naik, Haley B.
    Orgill, Dennis
    Poulin, Yves
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (01) : 91 - 101
  • [6] The Current Clinical Trial Landscape for Hidradenitis Suppurativa: A Narrative Review
    Hunt, Amanda
    Qian, Victoria
    Olds, Hailey
    Daveluy, Steven
    DERMATOLOGY AND THERAPY, 2023, 13 (07) : 1391 - 1407
  • [7] The Current Clinical Trial Landscape for Hidradenitis Suppurativa: A Narrative Review
    Amanda Hunt
    Victoria Qian
    Hailey Olds
    Steven Daveluy
    Dermatology and Therapy, 2023, 13 : 1391 - 1407
  • [8] 2 Topical, systemic and biologic therapies in hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms
    Frew, John W.
    Hawkes, Jason E.
    Krueger, James G.
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2019, 10
  • [9] Rifampin and clindamycin are safe long-term: Response to "North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations Part II: Topical, intralesional, and systemic medical management"
    Albrecht, Joerg
    Bigby, Michael
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 88 (01) : E31 - E31
  • [10] An Update on Hidradenitis Suppurativa (Part I): Epidemiology, Clinical Aspects, and Definition of Disease Severity
    Martorell, A.
    Garcia-Martinez, F. J.
    Jimenez-Gallo, D.
    Pascual, J. C.
    Pereyra-Rodriguez, J.
    Salgado, L.
    Vilarrasa, E.
    ACTAS DERMO-SIFILIOGRAFICAS, 2015, 106 (09): : 703 - 715
12